Hydroxyurea-Induced Pneumopathy in a Patient With Myeloproliferative Syndrome

Oriol Plans Galván; Hipólito Pérez Moltó; Ariadna Fabià-Mayans; Blanca Xicoy; José Luis Mate; Pilar Ricart Martí

doi:10.1177/1179547618770688

Clinical Medicine Insights: Case Reports (Apr 2018)

Hydroxyurea-Induced Pneumopathy in a Patient With Myeloproliferative Syndrome

Oriol Plans Galván,
Hipólito Pérez Moltó,
Ariadna Fabià-Mayans,
Blanca Xicoy,
José Luis Mate,
Pilar Ricart Martí

Affiliations

Oriol Plans Galván: Department of Intensive and Critical Care, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
Hipólito Pérez Moltó: Department of Intensive and Critical Care, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
Ariadna Fabià-Mayans: Department of Urology, Hospital Universitari Joan XXIII, Tarragona, Spain
Blanca Xicoy: Department of Hematology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
José Luis Mate: Department of Pathological Anatomy, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
Pilar Ricart Martí: Department of Intensive and Critical Care, Hospital Universitari Germans Trias i Pujol, Badalona, Spain

DOI: https://doi.org/10.1177/1179547618770688
Journal volume & issue: Vol. 11

Abstract

Read online

Hydroxyurea (HU) is a drug frequently used in the treatment of chronic myeloproliferative neoplasms. The most common side effects of this drug are pancytopenia, digestive and skin disorders. Respiratory complications are rare and there are less than 20 cases described, only 5 of which underwent an anatomopathological study. We present the case of a patient with chronic myeloproliferative neoplasm who developed interstitial pneumonitis probably due to HU according to histological study.

Published in Clinical Medicine Insights: Case Reports

ISSN: 1179-5476 (Online)
Publisher: SAGE Publishing
Country of publisher: United Kingdom
LCC subjects: Medicine: Medicine (General)
Website: https://journals.sagepub.com/home/icr

About the journal